Modernizing the Global Postal System: Zonos Selected by the Universal Postal Union (UPU) to Power Enhanced Compliance, Processing Speed, and Transparency for Posts Worldwide
4.9.2024 16:00:00 CEST | Business Wire | Press release
Zonos technology will help Posts overcome data transmission challenges, support regulatory compliance, and transition towards a more transparent and efficient Delivered Duty Paid (DDP) model, through the UPU’s Customs Declaration System (CDS).
In a groundbreaking move to address the dual challenges of evolving compliance regulations and increasing consumer expectations for swift, efficient deliveries, Zonos, the leader in cross-border technology solutions, has been selected by the Universal Postal Union (UPU) for a strategic initiative. The UPU is a United Nations specialized agency that facilitates international postal cooperation through its universal network of modern postal services. By leveraging Zonos' cutting-edge API technology to enhance the accuracy and processing speed of data transmitted through the UPU's Customs Declaration System (CDS), this effort is poised to transform the global postal ecosystem. This initiative aims to empower postal operators with technology to mitigate delays caused by inadequate or incomplete data, thereby improving operational efficiency, ensuring compliance, and significantly enhancing the delivery experience for consumers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904490189/en/
The international DDP shipping model allows parcels to ship with duties, taxes, and fees prepaid, making it easy for packages to move through customs. (Graphic: Business Wire)
Bridging the Technological Divide for Postal Operators Worldwide
This partnership specifically targets the technological challenges faced by postal operators around the globe. Many of these entities struggle to compete in an increasingly digital and data-driven landscape due to their limited ability to accurately and rapidly transmit electronic advanced data (EAD). This deficiency places them at a competitive disadvantage and contributes to significant delays in the international customs clearance process.
Zonos' innovative API technology offers a scalable and adaptable technology solution to these challenges, facilitating real-time, accurate data collection that meets the rigorous requirements of modern customs and security regulations that require detailed shipment information including good descriptions, harmonized codes, and accurate values for general or regional (such as ICS2) EAD regulations. The improved data quality addresses regulatory and safety concerns about the contents of packages for global customs operations.
Transitioning to a Delivered Duty Paid (DDP) Model
A significant goal of this collaboration is to transition towards a DDP model in response to market demand for more transparent and efficient customs processes. This initiative supports the UPU's Article 18-004 (Items for delivery free of charges and fees) by developing a robust DDP solution, facilitating smoother and faster cross-border mail and parcel deliveries. By enabling posts to calculate and collect duties and taxes at the point of sale, this model eliminates surprise costs for consumers and enhances the overall international mailing and delivery experience.
Enhancing Consumer Experience through Efficiency and Reliability
The UPU-Zonos initiative emphasizes improving the delivery experience for consumers worldwide. By streamlining the data collection process, the partnership aims to expedite customs clearance and reduce the time packages spend in transit to meet the consumer demand for speed. It also aims to enhance the reliability and predictability of international deliveries, fostering greater trust in the global postal system.
A Unified Vision for the Future of International Postal Services
The shared commitment of the UPU and Zonos to leveraging technology for the betterment of the global postal ecosystem is at the heart of this initiative. Clint Reid, CEO of Zonos, echoed this sentiment, highlighting the transformative potential of the collaboration: "Together, we are not just addressing immediate challenges; we are paving the way for a future where international postal services are more secure, efficient, and transparent for all."
About Zonos
Zonos is a leader in technology innovation for international commerce, simplifying cross-border trade with its comprehensive suite of solutions. Focused on compliance, classification, and transparent cost calculation, Zonos empowers businesses and postal operators to expand their global reach effortlessly, making international trade more accessible and transparent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904490189/en/
Contacts
Jennifer Meads, Head of Marketing at Zonos
Jennifer Meads, Head of Marketing at Zonos
media@zonos.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom